Lunasin Put To The Test For Lou Gehrig's Disease : Shots - Health News Fifty patients with Lou Gehrig's disease have volunteered for a study of a dietary supplement as an experimental treatment. Even a failure could help by eliminating a dead end from consideration.
NPR logo

Simplified Study Aims To Quickly Test A Long-Shot ALS Treatment

  • Download
  • <iframe src="https://www.npr.org/player/embed/499328778/499343677" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Simplified Study Aims To Quickly Test A Long-Shot ALS Treatment

Simplified Study Aims To Quickly Test A Long-Shot ALS Treatment

  • Download
  • <iframe src="https://www.npr.org/player/embed/499328778/499343677" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

ROBERT SIEGEL, HOST:

Studies of experimental drugs usually take many years and cost hundreds of millions of dollars. But here's a story about a study that is different. As NPR's Richard Harris reports, it's happening quickly because patients are demanding it.

RICHARD HARRIS, BYLINE: The study involves one of the most intractable of all diseases, ALS or Lou Gehrig's disease. This muscle-wasting disorder is almost always fatal within a matter of years. But an online community got interested in an extraordinary patient whose symptoms actually got better, not worse. Richard Bedlack, a neurologist at Duke University, said the man had taken a soy-based supplement called Lunasin.

RICHARD BEDLACK: And lo and behold, you know, six months later - speech back to normal, swallowing back to normal - doesn't use his feeding tube. Arms and legs - significantly stronger as measured by his therapist.

HARRIS: Now, of course, it could be just a coincidence that the man who got better happened to be taking these supplements. But many patients in the online ALS community clamored for more information. So to find out, Bedlack teamed up to run a study with Paul Wicks, a neuropsychologist at a website called PatientsLikeMe.

PAUL WICKS: So what we wanted to do was find a way of rapidly testing. You know, is there any possibility that a nutritional supplement could be beneficial here?

HARRIS: The study they came up with dispensed with many of the standard features of research that makes it so expensive, time-consuming and often so hard to recruit patients. They didn't have a comparison group taking a placebo. They didn't need safety testing because the supplement was already on the market.

Most important, they aren't looking for subtle effects like slower disease progression. That may be vital for a pharmaceutical company trying to get approval for a new drug. But it isn't really what patients want.

WICKS: I think what people are really looking for is to regain some function. And so, perhaps, we want to swing for the fences every now and then.

HARRIS: Chances are that it won't work. But at least, people will know and won't waste their time and money. That said...

WICKS: If we find just one patient that has a reversal the size of the initial index patient, that in itself is incredible because these cases of reversals are once a generation.

HARRIS: The study recruited 50 volunteers at a record pace for ALS research, Bedlack said. That's partly because it only requires three doctor's visits. These are frequently challenging for people with this debilitating disease. Most of the data are gathered virtually. Patients post their own weekly assessments in a secure area of the PatientsLikeMe website.

One participant is Karen Lorne, a 58-year-old nurse practitioner from Chapel Hill, N.C. This spring, she noticed she could no longer hold medical instruments in her left hand. And her speech started to slur. She was diagnosed with ALS in July. After considering her options, Lorne decided to sign up for the low-hassle trial with the supplement. She spoke via Skype.

KAREN LORNE: The virtual site allows me to kind of track objectively my progress and the progress of other patients.

HARRIS: That's anonymous, of course. Also important - it's a support group.

LORNE: So you can type in, I'm having a bad day, you know, and somebody will give you, you know, a list of pointers to help keep you in the center, which is where you really want to live.

HARRIS: And the study doesn't consume her precious days. She can still focus on her family and life's daily pleasures.

LORNE: We try to live in the present and enjoy every moment as thoroughly as possible. And, actually, some of my friends who do not have the disease say that, you know, me having it has helped them shore up their lives - starting to recognize what's important.

HARRIS: She's also helping to advance knowledge about ALS even if this trial doesn't end up helping her. Patients are a valuable resource. Yet Paul Wicks at PatientsLikeMe says only 10 percent ever end up in a study.

WICKS: If this infrastructure works, you know, in two years, could you imagine there being 20 trials like this one in parallel? You know, I mean, I have a question for the field. Why isn't every patient in a study?

HARRIS: Virtual studies like this could quickly identify promising ideas for scientists to pursue. And if the approach is successful, it could apply to other diseases, as well. Richard Harris, NPR News.

Copyright © 2016 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.